Great Lakes Advisors LLC Invests $3.73 Million in Denali Therapeutics Inc. $DNLI

Great Lakes Advisors LLC acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 145,045 shares of the company’s stock, valued at approximately $3,731,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new stake in Denali Therapeutics during the second quarter valued at approximately $360,759,000. Norges Bank bought a new position in shares of Denali Therapeutics in the 4th quarter worth $84,525,000. ADAR1 Capital Management LLC increased its holdings in shares of Denali Therapeutics by 3,490.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock worth $35,932,000 after buying an additional 1,819,339 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Denali Therapeutics by 77.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock valued at $63,329,000 after buying an additional 1,672,098 shares in the last quarter. Finally, Temasek Holdings Private Ltd raised its position in shares of Denali Therapeutics by 30.9% during the 4th quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock valued at $115,784,000 after buying an additional 1,657,142 shares in the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Trading Down 2.9%

Shares of DNLI stock opened at $24.95 on Friday. The business has a 50-day moving average of $24.39 and a 200 day moving average of $21.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. Denali Therapeutics Inc. has a 1-year low of $12.58 and a 1-year high of $27.30. The stock has a market capitalization of $3.99 billion, a PE ratio of -8.79 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $2.15 million. During the same quarter in the prior year, the business earned ($0.72) earnings per share. As a group, sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.59 earnings per share for the current year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the transaction, the insider owned 281,763 shares of the company’s stock, valued at $7,063,798.41. This represents a 1.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 9.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on DNLI shares. JPMorgan Chase & Co. started coverage on shares of Denali Therapeutics in a research report on Monday, July 13th. They issued an “overweight” rating and a $29.00 target price for the company. Wall Street Zen upgraded Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Morgan Stanley lifted their price target on Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft upped their price objective on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Finally, Robert W. Baird set a $34.00 price objective on Denali Therapeutics in a report on Friday, August 7th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.92.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.